In Duchenne muscular dystrophy (DMD), iPSC-derived myocytes allow mechanistic studies of muscle degeneration, and gene editing has restored dystrophin expression in vitro, highlighting therapeutic potential [58-60]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.